Photo of William F Pirl,  MD, MPH

William F Pirl, MD, MPH

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2691


william_pirl@dfci.harvard.edu

William F Pirl, MD, MPH

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Psychiatry, Harvard Medical School
  • Vice Chair for Psychosocial Oncology, Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • Wong RL, El-Jawahri A, D'Arpino SM, Fuh CX, Johnson PC, Lage DE, Irwin KE, Pirl WF, Traeger L, Cashavelly BJ, Jackson VA, Greer JA, Ryan DP, Hochberg EP, Temel JS, Nipp RD. Use of Antidepressant Medications Moderates the Relationship Between Depressive Symptoms and Hospital Length of Stay in Patients with Advanced Cancer. Oncologist 2018. PubMed
  • Pirl WF, Saez-Flores E, Schlumbrecht M, Nipp R, Traeger LN, Kobetz E. Race and Ethnicity in the Evidence for Integrating Palliative Care Into Oncology. J Oncol Pract 2018; 14:e346-e356. PubMed
  • Bail JR, Traeger L, Pirl WF, Bakitas MA. Psychological Symptoms in Advanced Cancer. Semin Oncol Nurs 2018; 34:241-251. PubMed
  • Pirl WF, Greer JA, Park E, Safren SA, Fields L, Wood L, Traeger L, El-Jawahri A, Zebrack B, Temel JS. Development and evaluation of a six-day training program in supportive oncology research. 2018. PubMed
  • Jacobs JM, Traeger L, Eusebio J, Simon NM, Sequist LV, Greer JA, Temel JS, Pirl WF. Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study. J Psychosom Res 2017; 99:28-33. PubMed
  • Pirl WF, Greer JA, Irwin K, Lennes IT, Jackson VA, Park ER, Fujisawa D, Wright AA, Temel JS. Processes of discontinuing chemotherapy for metastatic non-small-cell lung cancer at the end of life. J Oncol Pract 2015. PubMed
  • Seay J, Mitteldorf D, Yankie A, Pirl WF, Kobetz E, Schlumbrecht M. Survivorship care needs among LGBT cancer survivors. J Psychosoc Oncol 2018; 36:393-405. PubMed